title: Bevacizumab, sunitinib: osteonecrosis of the jaw.
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000494:pharmacology; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000494:pharmacology; D007571:Jaw Diseases / Q000139:chemically induced* / Q000473:pathology; D010020:Osteonecrosis / Q000139:chemically induced*; D011758:Pyrroles / Q000009:adverse effects / Q000494:pharmacology; D000077210:Sunitinib; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007211:Indoles; D011758:Pyrroles; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000077210:Sunitinib